BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

SEC Filings
Form 6-K
BIOLINERX LTD. filed this Form 6-K on 02/07/2019
Document Outline
Entire Document (639.4 KB)
Subdocument 1 - 6-K - 6-K
Page 1 - SECURITIES AND EXCHANGE COMMISSION
Page 2 - Item 8.01 Other Events.
Page 3 - N/A
Subdocument 2 - EX-99 - UNDERWRITING AGREEMENT, DATED FEBRUARY 5, 2019
Page 1 - Exhibit 1.1
Page 2 - BIOLINERX LTD.
Page 3 - DepositaryDeposit Agreement
Page 4 - Preliminary ProspectusPricing ProspectusProspectus
Page 5 - NasdaqCMTASE
Page 6 - Underwriters Information
Page 7 - Auditor
Page 8 - N/A
Page 9 - Companies Law
Page 10 - SubsidiarySubsidiaries
Page 11 - OECD ConventionFCPA
Page 12 - Money Laundering Laws
Page 13 - Lock-Up Period
Page 14 - Intellectual Property Rights
Page 15 - rights-of-way
Page 16 - Environmental Laws
Page 17 - Applicable LawsAuthorizations
Page 18 - Sanctions
Page 19 - N/A
Page 20 - Chief ScientistInvestment Center
Page 21 - Share OptionsCompany Share Plans
Page 22 - Rule 172
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - providedhowever
Page 30 - Underwriter
Page 31 - N/A
Page 32 - N/A
Page 33 - N/A
Page 34 - [Signature Page Follows]
Page 35 - N/A
Page 36 - SCHEDULE I
Page 37 - SCHEDULE II-A
Page 38 - SCHEDULE II-B
Page 39 - SCHEDULE III
Page 40 - SCHEDULE IV
Page 41 - EXHIBIT A
Page 42 - EXHIBIT B
Page 43 - [signature page follows]
Page 44 - N/A
Subdocument 3 - EX-99 - FORM OF WARRANT
Page 1 - Exhibit 4.1
Page 2 - DepositaryADSs Delivery DateDWAC
Page 3 - Exercise Price
Page 4 - Cashless Exercise
Page 5 - Maximum Percentage1934 ActSECReported Outstanding Share NumberReduction SharesExcess Shares
Page 6 - Required Reserve AmountAuthorized ADS Allocation
Page 7 - Distribution
Page 8 - Purchase Rights
Page 9 - Corporate EventCorporate Event Consideration
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL
Page 14 - Affiliate
Page 15 - Attribution Parties
Page 16 - Change of Control
Page 17 - Eligible Market
Page 18 - Group
Page 19 - Subject Entity
Page 20 - IN WITNESS WHEREOF,
Page 21 - EXHIBIT A
Page 22 - N/A
Page 23 - ACKNOWLEDGMENT
Subdocument 4 - EX-99 - OPINION OF YIGAL ARNON & CO., ISRAELI COUNSEL TO THE COMPANY
Page 1 - Exhibit 5.1
Page 2 - N/A
Subdocument 5 - EX-99 - OPINION OF MAYER BROWN LLP, U.S. COUNSEL TO THE COMPANY
Page 1 - Exhibit 5.2
Page 2 - N/A
Subdocument 6 - EX-99.1 - PRESS RELEASE
Page 1 - Exhibit 99.1
Page 2 - Various statements in this release concerning BioLineRx s future expectations constitute forward-loo


Interview with Philip Serlin, CEO
December 2016